JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 22, 2004; DOI: 10.1124/jpet.104.072991


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.072991v1
312/1/407    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Todorov, L.
Right arrow Articles by Westfall, D. P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Todorov, L.
Right arrow Articles by Westfall, D. P
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH


Received for publication June 21, 2004.
Revised October 16, 2004.
Accepted for publication October 18, 2004.

Facilitation of the Purinergic Contractile Response of the Guinea Pig Vas Deferens by Sodium Orthovanadate

Latchezar Todorov 1*, Svetlana T Mihaylova-Todorova 1, Sophie M Choe 1, David P Westfall 1

1 University of Nevada School of Medicine

* Address correspondence to: E-mail: todorov{at}med.unr.edu

Abstract

Experiments were carried out to examine the effects of protein tyrosine kinase (PTK) and protein tyrosine phosphatase (PTP) inhibitors on the purinergic contraction of the guinea pig vas deferens. Sodium orthovanadate (SOV) produced a robust increase of the amplitude of contractions evoked by both neurogenic electrical field stimulation and exogenous ATP. This effect of SOV was concentration and time-dependent, as well as, reversible and reproducible. Genistein, a PTK inhibitor, but not its inactive structural analogue daidzein, inhibited the SOV-induced facilitation of the purinergic contraction. Another PTK inhibitor, 2,5-dihydroxycinnamic acid methyl ester, which is structurally unrelated to genistein, also inhibited the facilitation effects of SOV. While an application of as low as 3 µM of these inhibitors significantly decreased the effect of SOV, other PTK inhibitors, namely butein, levandustin C and thyrphostin 23 were less effective even at concentrations of 100 µM. Western blot experiments showed that the facilitation of the purinergic contraction by SOV is associated with a prominent increase in the level of tyrosine phosphorylation of proteins with estimated molecular sizes of 180 and 123 kDa, which was reversed in the presence of genistein. Evidence is also presented that argue against the possibility that inhibition of the Na+/K+-ATPase or ATPases, responsible for the clearance of ATP is involved in the SOV-induced facilitation of the purinergic contraction. Together these results suggest that the responsiveness of the smooth muscle of the vas deferens to the actions of ATP is modulated via a previously unidentified mechanism, which may involve protein tyrosine phosphorylation.


Key words: Contraction, Protein Tyrosine Phosphorylation, Purinergic, Smooth Muscle, Sodium Orthovanadate, Vas Deferens





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.